New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO ® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events
RARITAN, NJ, September 27, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data from the Phase 3 UNIVERSE study showing treatment with XARELTO® (rivaroxaban) in an oral suspension formulation, compared to treatment with aspirin, was associated with numerically fewer blood clots and clinical events strongly associated with blood clots in pediatric patients (aged 2-8 years) who have undergone the Fontan procedure. [1] These findings, which were published this month in the Journal of the American Heart Association and included in a recent New Drug Application submitted to the...
Source: Johnson and Johnson - September 27, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

2021 Lasker Awards Honor Work in mRNA Vaccines, Neuroscience and More
The prizes are given annually, and many winners often go on to be awarded the Nobel Prize. (Source: NYT Health)
Source: NYT Health - September 24, 2021 Category: Consumer Health News Authors: Gina Kolata Tags: Lasker Awards Science and Technology Medicine and Health Kariko, Katalin (1955- ) Weissman, Drew (1961- ) Deisseroth, Karl Baltimore, David (1938- ) Hegemann, Peter Oesterhelt, Dieter RNA (Ribonucleic Acid) Vaccination and Immunization Source Type: news

2021 Lasker Awards Honor Neuroscience Researchers, A Biomedical Legend And mRNA Vaccine Pioneers
This year ’s awards, sometimes nicknamed “America’s Nobels,” honors the researchers who developed the foundation for Covid-19 vaccines and other medical innovators. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 24, 2021 Category: Pharmaceuticals Authors: Alex Knapp, Forbes Staff Tags: Science /science Innovation /innovation Healthcare /healthcare Editors' Pick editors-pick Breaking breaking-news Coronavirus technology alexknappblog Source Type: news

Roche presents new data at World Muscle Society (WMS) 2021 highlighting new advances for people living with rare neuromuscular disorders
Basel, 24 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data from across its growing neuromuscular portfolio at the World Muscle Society (WMS) Virtual Congress 20 – 24 September 2021. The presentations included additional results from the RAINBOWFISH study, evaluating the efficacy and safety of Evrysdi® (risdiplam) in babies with pre-symptomatic spinal muscular atrophy (SMA) from birth to six weeks of age and data supporting the continued clinical investig ation of gene therapy, SRP-9001, in Duchenne muscular dystrophy (DMD).“These new data for Evrysdi may help extend the potential ben...
Source: Roche Media News - September 24, 2021 Category: Pharmaceuticals Source Type: news

Roche presents new data at World Muscle Society (WMS) 2021 highlighting new advances for people living with rare neuromuscular disorders
Basel, 24 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data from across its growing neuromuscular portfolio at the World Muscle Society (WMS) Virtual Congress 20 – 24 September 2021. The presentations included additional results from the RAINBOWFISH study, evaluating the efficacy and safety of Evrysdi® (risdiplam) in babies with pre-symptomatic spinal muscular atrophy (SMA) from birth to six weeks of age and data supporting the continued clinical investig ation of gene therapy, SRP-9001, in Duchenne muscular dystrophy (DMD).“These new data for Evrysdi may help extend the potential ben...
Source: Roche Investor Update - September 24, 2021 Category: Pharmaceuticals Source Type: news

UCLA Broad Stem Cell Research Center receives $5 million CIRM grant for research training program
TheEli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLAhas been awarded $5 million by the California Institute for Regenerative Medicine, the state ’s stem cell agency, to train young scientists and physicians to become leaders in the stem cell and regenerative medicine field.The five-year grant will enable the center to expand its Stem Cell Training Program, which was established in 2006 and funded by CIRM until 2015, when the agency changed its funding priorities. Since then, the program has been sustained by philanthropy. With the passage of Proposition 14 last fall, however, CIRM ha...
Source: UCLA Newsroom: Health Sciences - September 23, 2021 Category: Universities & Medical Training Source Type: news

Richard Powers on His Latest Book, Bewilderment —And Why Children Are the Ones to Call Out Climate Change Evasion
Richard Powers’ 2018 novel The Overstory, which won that year’s Pulitzer Prize for Fiction, followed decades of the MacArthur Fellow’s work investigating the intersections of culture, the environment, science and technology. His most recent book, Bewilderment, released Tuesday, again delves into the impact of science on human life. Bewilderment by Richard Powers In Bewilderment, something of a contemporary take on the Flowers for Algernon story, Powers writes of a neurodivergent, middle-school-aged child named Robin who undergoes an experiment involving decoded neurofeedback (a cutting-edge neuroscience...
Source: TIME: Science - September 23, 2021 Category: Science Authors: Elijah Wolfson Tags: Uncategorized Books climate change Source Type: news

Developmental Nicotine Exposure in Mice Affects Epigenetic Factors in the Brain Across Multiple Generations
Epigenetic changes that can persist for generations after nicotine exposure may predispose children and grandchildren of people who smoke to develop neurological and behavioral disorders. (Source: NIDA News)
Source: NIDA News - September 22, 2021 Category: Addiction Tags: Genetics, Genetics, Nicotine, NIDA Notes, Basic Science Source Type: news

Opioids, pain, and the brain: Mapping out a healthier future for women
A Women ’s Health Research at Yale-funded study will be one of the first to investigate sex differences within the neurobiology of pain and analgesia. (Source: Yale Science and Health News)
Source: Yale Science and Health News - September 21, 2021 Category: Universities & Medical Training Source Type: news

Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S.
This study compared approximately 390,000 people who received the Company’s single-shot COVID-19 vaccine versus approximately 1.52 million unvaccinated people matched on age, sex, time, three-digit zip code, and comorbidities and predictors for COVID-19 infection severity.This study is a longitudinal cohort design, using robust propensity matching methods to create a comparator cohort to assess real-world VE. All analyses were performed using the Aetion Evidence Platform, which is a scientifically validated software that is also used by regulators, payers, and health technology assessment bodies to assess the safety,...
Source: Johnson and Johnson - September 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Data on RYBREVANT ® (amivantamab-vmjw) in Combination with Lazertinib Show Early Activity in Patients with Non-Small Cell Lung Cancer Whose Disease Has Progressed After Both Osimertinib and Platinum-Based Chemotherapy
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary results from the Phase 1b CHRYSALIS-2 (NCT04077463) study evaluating RYBREVANT® (amivantamab-vmjw) in combination with lazertinib in the treatment of patients with non-small cell lung cancer (NSCLC) characterized by epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations whose disease had progressed after treatment with osimertinib and platinum chemotherapy.[i] While previously reported results have demonstrated durable responses with RYBREVANT® in combination with...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

RYBREVANT ® (amivantamab-vmjw) Provides Higher Activity and Longer Duration of Response When Used in Combination with Lazertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer Who Have Failed Osimertinib
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new analysis from the CHRYSALIS (NCT02609776) study evaluating RYBREVANT® (amivantamab-vmjw) monotherapy and a combination regimen with lazertinib in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations who progressed after osimertinib.[1] The analysis showed higher activity and longer duration of response (DOR) in patients treated with the combination therapy, demonstrating the potential benefit of targeting the extracellular (outer) and catal...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Results from Phase 1b/2 NORSE Study in Patients with Metastatic or Locally Advanced Urothelial Carcinoma Treated with BALVERSA ® (erdafitinib) in Combination with Cetrelimab, a PD-1 Inhibitor
September 17, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1b/2 NORSE (NCT03473743) study evaluating BALVERSA® (erdafitinib) in combination with cetrelimab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody, compared to BALVERSA® monotherapy in patients with locally advanced or metastatic urothelial carcinoma (mUC) with fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alterations who are ineligible for cisplatin, a current standard of care treatment for mUC. The results were highlighted in an oral present...
Source: Johnson and Johnson - September 17, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Pioneering Research in E3 Ubiquitin Ligase Biology and Applications to Drug Discovery
Jennifer Johnston discusses how a better understanding of ubiquitin-proteasome system elements can potentially aid neurodegenerative disease therapeutics. (Source: The Scientist)
Source: The Scientist - September 15, 2021 Category: Science Tags: Sponsored Webinars Source Type: news

Johnson & Johnson Ebola Vaccine Regimen Demonstrated Robust and Durable Immune Response in Adults and Children in Data Published in The Lancet Infectious Diseases
NEW BRUNSWICK, N.J., September 13, 2021 – Data from two papers published in The Lancet Infectious Diseases demonstrated that the Johnson & Johnson (the Company) Ebola vaccine regimen, Zabdeno® (Ad26.ZEBOV) and Mvabea® (MVA-BN-Filo), generated robust humoral (antibody) immune responses in adults and children (ages 1-17) with the immune responses persisting in adults for at least two years. The data also showed that booster vaccination with Ad26.ZEBOV, administered to adults two years after the initial vaccination, induced a strong anamnestic (immune) response within seven days. These findings support the p...
Source: Johnson and Johnson - September 13, 2021 Category: Pharmaceuticals Source Type: news

ERLEADA ® (apalutamide) Oral Presentations Demonstrate Importance of Prostate Specific Antigen (PSA) as Key Efficacy Indicator and Show Strong Patient Adherence Rates
September 11, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data demonstrating robust prostate-specific antigen (PSA) response and strong adherence rates in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with ERLEADA® (apalutamide) in the real-world clinical setting. The strong PSA response was also seen in a separate post-hoc analysis that showed a correlation between rapid and deep PSA response and prolonged survival in both metastatic castration-sensitive prostate cancer (mCSPC) and nmCRPC. The post-hoc analysis also...
Source: Johnson and Johnson - September 12, 2021 Category: Pharmaceuticals Source Type: news

Tumors Disrupt the Blood-Brain Barrier at a Distance
Shoring up the tissues that separate neurons and other brain cells from the circulatory system in fruit flies and mice can prolong life in the presence of a tumor. (Source: The Scientist)
Source: The Scientist - September 9, 2021 Category: Science Tags: News & Opinion Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate can...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Israel: one-year-old conjoined twin girls see each other for the first time after surgery – video
One-year-old twin girls have looked at each other for the first time after a complex surgery to separate them at Soroka medical centre in Beersheba, Israel. Dozens of experts from Israel and abroad were involved in the preparation and 12-hour procedure. The team used 3D- and virtual-reality models to map the complex operation. This enabled simulations and practice to be undertaken before the actual procedure.Soroka's chief paediatric neurosurgeon, Mickey Gideon, said: 'We have done the reconstruction of the brain membrane, a reconstruction of the skull and now the plastic surgeons continue the surgery for th...
Source: Guardian Unlimited Science - September 6, 2021 Category: Science Tags: Israel Medical research World news Source Type: news

Neuroscience and the misperception of reality | Letter
As living creatures, we are exquisitely evolved to interact with the world through perception, saysDavid HughesGaia Vince, reviewing Anil Seth ’s Being You: A New Science of Consciousness (The exhilarating new science of consciousness, 25 August), extols the thesis that because our perception of the world is a complex physical process, perception is itself a “hallucination” and “a big lie created by our deceptive brains”. But when we consider that dogs hear sounds we don’t, flies look through compound eyes, birds navigate using inbuilt GPS, it does seem perverse to claim that the very ph...
Source: Guardian Unlimited Science - September 3, 2021 Category: Science Authors: Letters Tags: Neuroscience Psychology Science and nature books Consciousness Source Type: news

What Is ‘Tragic Optimism’ and Can It Help Us Make Sense Of This Moment?
Well hello! I’m so glad you’re here. A version of this article also appeared in the It’s Not Just You newsletter. Sign up to get a new edition every Saturday. After another week of searing headlines about just about everything—global climate issues, the unfurling tragedies in Afghanistan, in Louisiana and parts south, the pandemic—all of it left me sleepless and sad and cynical. The latter is the most corrosive emotion I can think of right now, and when I’m not that ditch, it’s getting harder to imagine what our future looks like as the sands continue to sink and shift beneath our ...
Source: TIME: Health - September 2, 2021 Category: Consumer Health News Authors: Susanna Schrobsdorff Tags: Uncategorized It's Not Just You Source Type: news

NIDCR's Fall 2021 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Fall 2021 E-Newsletter In this issue: NIDCR News Funding Opportunities & Related Notices NIH/HHS News Subscribe to NICDR News Science Advances   NIDCR News 5 Q&As About “Oral Health in America: Advances and Challenges” NIDCR issued a brief Q&A regarding details of the forthcoming report Oral Health in America: Advances and Challenges, which will be published in Fall 2021. This comprehensive report will examine improvements in oral health over t...
Source: NIDCR Science News - September 1, 2021 Category: Dentistry Source Type: news

Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA a...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021
August 31, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple company-sponsored presentations in prostate and bladder cancers will be highlighted at the virtual 2021 American Urological Association Annual Meeting (AUA 2021), September 10-13. “Janssen maintains a strong commitment to advancing innovation and new therapeutic options for patients with genitourinary malignancies. As the treatment of genitourinary cancers becomes more complex, we continue to work with urologists and their teams to improve outcomes for patients across the continuum of disease...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa
This study is being conducted in the Americas and Europe where different strains of HIV are circulating. Given these differentiating factors and following consultations with the Mosaico study independent Data and Safety Monitoring Board (DSMB), it was decided that the Mosaico study will continue at this time. “We are extremely grateful to the women who volunteered for the Imbokodo study, and to our partners, including the people on the frontlines, all of whom are contributing every day to this enduring quest to make HIV history,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scien...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

I have a 50/50 chance of inheriting Huntington ’s disease – should I take a test to find out? | Lillian Hanly
A coin toss could give me two completely different lives. But once I know the result there ’s no going backI ’ve spent most of my life knowing I may have inherited a faulty gene that would causeHuntington ’s disease, a neurodegenerative disease that can be fatal. My grandad had the disease, my mum has it, and I am yet to take the test to find out if I have it too. It ’s a 50/50 chance of inheritance. Right now, I am happily ignorant of whether I carry the mutation or not. A coin toss could give me two completely different lives. Once I know the results, there’s no going back. So far, everyone ...
Source: Guardian Unlimited Science - August 30, 2021 Category: Science Authors: Lillian Hanly Tags: New Zealand Huntington's disease Asia Pacific World news Science Source Type: news

IQs are on the rise, but we don ’t need hard facts any more | Torsten Bell
Skills and reasoning are more vital than ever and the internet is taking the place of memorising by roteLet ’s start with the good news: we’re getting brighter. Sadly, not individually as we age, but IQs have risen over time, with new generations having higher reasoning skill scores than their predecessors. This progress on abstract reasoning is in contrast to plateauing or declining scores for retain ed knowledge such as vocabulary.Better nutrition or healthcare might explain some of this improvement. But there ’s also been a greater focus on skills over knowledge by schools and parents. This was what Mi...
Source: Guardian Unlimited Science - August 29, 2021 Category: Science Authors: Torsten Bell Tags: Psychology Science Neuroscience Source Type: news

Hearing mother ’s voice can lessen pain in premature babies, study suggests
Researchers measured pain responses in preterm babies during routine procedures in neonatal unitPremature babies appear to feel less pain during medical procedures when they are spoken to by their mothers, researchers have found.Babies that are born very early often have to spend time in neonatal intensive care units, and may need several painful clinical procedures. The situation can also mean lengthy separation from parents.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - August 27, 2021 Category: Science Authors: Nicola Davis Science correspondent Tags: Children's health Neuroscience Parents and parenting Hospitals Source Type: news

Johnson & Johnson Announces Data to Support Boosting its Single-Shot COVID-19 Vaccine
NEW BRUNSWICK, N.J., August 25, 2021 – Johnson & Johnson today announced data supporting the use of its COVID-19 vaccine as a booster shot for people previously vaccinated with the single-shot Johnson & Johnson vaccine. In July, the Company reported interim Phase 1/2a data published in the New England Journal of Medicine that demonstrated neutralizing antibody responses generated by the Johnson & Johnson single-shot COVID-19 vaccine were strong and stable through eight months after immunization. In anticipation of the potential need for boosters, the Company conducted two Phase 1/2a studies in individuals...
Source: Johnson and Johnson - August 25, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Being You by Professor Anil Seth review – the exhilarating new science of consciousness
Our world and the self are constructions of the brain, a pioneering neuroscientist arguesFor every stoner who has been overcome with profound insight and drawled, “Reality is a construct, maaan,” here is the astonishing affirmation. Reality – or, at least, our perception of it – is a “controlled hallucination”, according to the neuroscientist Anil Seth. Everything we see, hear and perceive around us, our whole beautiful world, is a big lie created by our deceptive brains, like a forever version ofThe Truman Show, to placate us into living our lives.Our minds invent for us a universe of c...
Source: Guardian Unlimited Science - August 25, 2021 Category: Science Authors: Gaia Vince Tags: Science and nature books Culture Consciousness Psychology Neuroscience Philosophy books Source Type: news

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) e...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

What Is Nanotechnology And How Is It Impacting Neuroscience?
Nanotechnology and nanoengineering are enabling neuroscience in ways never before possible. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - August 24, 2021 Category: Pharmaceuticals Authors: Gabriel A. Silva, Contributor Tags: Science /science Innovation /innovation Healthcare /healthcare Source Type: news

Listening To Songs Can Help Language Recovery After Stroke
New research suggests that listening to vocal music can kickstart language recovery after stroke more successfully than listening to audiobooks, because music encourages neuroplasticity in the language region of the brain. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - August 23, 2021 Category: Pharmaceuticals Authors: Eva Amsen, Contributor Tags: Science /science Innovation /innovation Healthcare /healthcare Source Type: news

Neuroscientist Anil Seth: ‘We risk not understanding the central mystery of life’
The professor of cognitive and computational neuroscience discusses his work to develop a scientific explanation for how the brain conjures consciousnessFor centuries, philosophers have theorised about the mind-body question, debating the relationship between the physical matter of the brain and the conscious mental activity it somehow creates. Even with advances in neuroscience and brain imaging techniques, large parts of that fundamental relationship remain stubbornly mysterious. It was with good reason that, in 1995, the cognitive scientist David Chalmers coined the term “the hard problem” to describe the qu...
Source: Guardian Unlimited Science - August 22, 2021 Category: Science Authors: Tim Adams Tags: Consciousness Neuroscience Books Culture Daniel Dennett Human biology Psychology Artificial intelligence (AI) Source Type: news

Life ’s Edge by Carl Zimmer review – what does it mean to be alive?
This profound meditation on the science of life explores where it has come from and how it evolvesAt a medical research laboratory in California, Alysson Muotri has used chemistry to change skin cells into neurons, which have multiplied to form “organoids” – globes of interconnected brain cells. The organoids can expand to hundreds of thousands of cells, live for years, and even produce detectable patterns of brain waves, like those of premature babies. “The most incredible thing is that they build themselves,” says Muotri. He ev en wonders whether they could one day become conscious.Such unse...
Source: Guardian Unlimited Science - August 21, 2021 Category: Science Authors: PD Smith Tags: Science and nature books Culture Society books Source Type: news

Neuron-Released Protein Can Set Off Inflammation: Study
Research in mice suggests that moderating nerve activity with drugs or electrical pulses could modify tissue immune responses, curtailing the chronic pain often associated with inflammatory... (Source: The Scientist)
Source: The Scientist - August 19, 2021 Category: Science Tags: News & Opinion Source Type: news

Janssen Presents Phase 1 Results for RYBREVANTTM (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
August 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary data from the Phase 1 CHRYSALIS study evaluating RYBREVANTTM (amivantamab-vmjw) for the treatment of patients with non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations. The initial data showed anti-tumor activity in patients with METex14 mutations and a safety profile consistent with reported experience at the approved CHRYSALIS Phase 2 dose (RYBREVANTTM 1050 mg [
Source: Johnson and Johnson - August 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Roche receives FDA approval for first companion diagnostic to identify dMMR solid tumour patients eligible for anti-PD-1 immunotherapy
Basel, 18 August 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval of the VENTANA MMR RxDx Panel, advancing the company's commitment to personalised healthcare through tests that determine which patients are most likely to benefit from specific and targeted therapies. The VENTANA MMR RxDx Panel is the first companion diagnostic test to aid in identifying patients whose solid tumours are deficient in DNA mismatch repair (MMR), who may be eligible for JEMPERLI (dostarlimab-gxly) monotherapy, an anti-PD-1 immunotherapy from GSK. The test evaluates a panel of MMR p...
Source: Roche Media News - August 18, 2021 Category: Pharmaceuticals Source Type: news

Roche receives FDA approval for first companion diagnostic to identify dMMR solid tumour patients eligible for anti-PD-1 immunotherapy
Basel, 18 August 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval of the VENTANA MMR RxDx Panel, advancing the company's commitment to personalised healthcare through tests that determine which patients are most likely to benefit from specific and targeted therapies. The VENTANA MMR RxDx Panel is the first companion diagnostic test to aid in identifying patients whose solid tumours are deficient in DNA mismatch repair (MMR), who may be eligible for JEMPERLI (dostarlimab-gxly) monotherapy, an anti-PD-1 immunotherapy from GSK. The test evaluates a panel of MMR p...
Source: Roche Investor Update - August 18, 2021 Category: Pharmaceuticals Source Type: news

Cuttlefish remember details of their last meal, study finds
The large-brained cephalopods can remember details of what, where and when even in their old ageCuttlefish have one of the largest brains among invertebrates and can remember what, where, and when specific things happened right up to their final days of life, according to new research.The cephalopods – which have three hearts, eight arms, blue-green blood, regenerating limbs, and the ability to camouflage andexert self-control– only live for roughly two years.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - August 17, 2021 Category: Science Authors: Natalie Grover Tags: Animals Zoology Biology Science Neuroscience World news Source Type: news

What ’s it like living with a phenomenal memory and can it be learned?
Both nature and nurture contribute to incredible recall skills and for those who have them there are benefits and drawbacks“17 April 2001?” I ask Krystyna Glowacki, 24, over Zoom.“That was a Tuesday,” she shoots back after less than half a beat. It was.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - August 14, 2021 Category: Science Authors: Gary Nunn Tags: Memory Australian lifestyle Australia news Science Neuroscience Source Type: news

Participant ’s Diagnosis Halts Gene Therapy Clinical Trial
The FDA pauses the research program on a lentivirus-based treatment for a rare neurological condition after a patient developed a bone marrow disorder that could presage leukemia. (Source: The Scientist)
Source: The Scientist - August 12, 2021 Category: Science Tags: News & Opinion Source Type: news

Dialing Down Pain from the Brain
Having trouble viewing this email? View it as a Web page. The latest science news from NIDCR's scientists and grantees The latest from NIDCR researchers and grantees Dialing Down Pain from the Brain NIDCR neuroscientist Yuanyuan "Kevin" Liu found a brain region that acts as a volume control for pain. NIDCR • August 12, 2021 STAY CONNECTED     (Source: NIDCR Science News)
Source: NIDCR Science News - August 12, 2021 Category: Dentistry Source Type: news

"Learning to listen to them and ask the right questions." Bennet Omalu, scientific objectivities, and the witnessing of a concussion crisis - Hollin G.
The death of American Football player Mike Webster has become foundational to narratives of sport's twenty-first century concussion crisis. Bennet Omalu, the neuropathologist who conducted Webster's autopsy and subsequently diagnosed Webster with Chronic T... (Source: SafetyLit)
Source: SafetyLit - August 11, 2021 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

I ’m Your Man review – Dan Stevens is the perfect date in android romance
Near-future tale of a woman who accepts a male ‘companion’ robot played by Stevens is laboriously told and not really funny enoughDirected by Maria Schrader, this was a crowd-pleasing favourite at the Berlin film festival earlier this year and its star, Maren Eggert, won the festival ’s new gender-neutral best leading performance prize. But I was disappointed with a film whose crises and dilemmas seem laborious and essentially predictable; it does not fully work as sci-fi or satire or comedy.We are in a world of the near-future (and the city of Berlin itself is certainly very plausible as its location). E...
Source: Guardian Unlimited Science - August 11, 2021 Category: Science Authors: Peter Bradshaw Tags: Film Comedy films Science fiction and fantasy films Dan Stevens Germany Artificial intelligence (AI) World news Technology Europe Culture Consciousness Computing Human biology Neuroscience Psychology Source Type: news

‘This Is Really Scary’: Kids Struggle With Long Covid
Lingering physical, mental and neurological symptoms are affecting children as well as adults, including many who had mild reactions to the initial coronavirus infection. (Source: NYT Health)
Source: NYT Health - August 9, 2021 Category: Consumer Health News Authors: Pam Belluck Tags: your-feed-science Chronic Condition (Health) Coronavirus (2019-nCoV) Children and Childhood Mental Health and Disorders Brain Education (K-12) your-feed-healthcare Source Type: news

Clinics Won ’t Provide It. Insurers Won’t Cover It. So Will the First Alzheimer’s Drug Make a Difference?
In theory, the approval of the first drug to treat Alzheimer’s disease would be cause for universal celebration. But from the moment the U.S. Food and Drug Administration (FDA) approved aducanumab on June 7, the drug has been beset by controversy about whether the drug is actually effective—and if the agency bent to pressure from maker Biogen. The conflict came to a head Wednesday when the agency watchdog, the U.S. Department of Health and Human Services Inspector General, announced that it would look into the drug’s accelerated approval, including allegations that the FDA had an “inappropriately cl...
Source: TIME: Health - August 5, 2021 Category: Consumer Health News Authors: Alice Park and Tara Law Tags: Uncategorized Drugs healthscienceclimate Source Type: news

New mothers ’ sleep loss linked to accelerated aging
When new mothers complain that all those sleepless nights caring for their newborns are taking years off their life, they just might be right, UCLA research published this summer in the journalSleep Healthsuggests.Scientists studied 33 mothers during their pregnancies and the first year of their babies ’ lives, analyzing the women’s DNA from blood samples to determine their “biological age,” which can differ from chronological age. They found that a year after giving birth, the biological age of mothers who slept less than seven hours a night at the six-month mark was three to seven years older than...
Source: UCLA Newsroom: Health Sciences - August 5, 2021 Category: Universities & Medical Training Source Type: news

Science Saturday: Regenerative pipeline for spinal cord repair
Mayo Clinic  research is learning how stem cell therapy can treat neurodegenerative diseases. Mayo is among the first to study whether stem cell therapy might trigger healing for spinal cord injury. Research is ongoing in preclinical models, but it also has advanced from discovery science to early clinical tr ials. It's a complex question because different forms of stem cells can be derived from different biologics within the body. Mayo Clinic's Center for Regenerative Medicine is driving the research that… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - July 31, 2021 Category: Databases & Libraries Source Type: news

UPTRAVI ® (selexipag) Receives FDA Approval for Intravenous Use in Adult Patients with Pulmonary Arterial Hypertension (PAH)
TITUSVILLE, N.J. – July 30, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved UPTRAVI® (selexipag) injection for intravenous (IV) use for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adult patients with WHO functional class (FC) II–III, who are temporarily unable to take oral therapy. UPTRAVI® IV is a therapeutic option that will allow patients to avoid short-term treatment interruptions and stay on UPTRAVI® therapy, as uninterrupted treatment is considered key for individ...
Source: Johnson and Johnson - July 30, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news